A combination of antiretrovirals, broadly neutralizing antibodies and leronlimab limits viral reservoir in monkey study.
POZ news story
A three-prong strategy combining antiretroviral therapy, broadly neutralizing antibodies and the CCR5-blocking antibody leronlimab may limit the size of the HIV reservoir in infants, potentially paving the way for a functional cure, according to research published in Nature Microbiology.
“These findings suggest a synergy between broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade for preventing viral reservoir establishment and offer potential improvements over current therapies for newborns exposed to [HIV],” the researchers wrote.
“The really exciting part is that it could go to clinical trials immediately to eliminate HIV infection in newborns. The next step after that is to test if this can work in newly exposed adults,” lead author Jonah Sacha, PhD, of the Oregon National Primate Research Center at the Oregon Health & Science University, said in a news release. Sacha discussed the potential of CCR5-based therapy for an HIV cure at the recent International AIDS Conference, suggesting that leronlimab might enable more people with HIV and cancer to be cured with stem cell transplants.
Read the full news story here.
Source : POZ
Related HIV and Co-Infections News
-
Emory University: Cancer medication helps reduce SIV reservoir, increases hope for HIV cure
-
[Press release] FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children
-
[AIDS 2026] aidsmap: ‘We finally understand what we have to do’: antibody studies point the way to an HIV cure
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.